adults had already taken GLP-1 at some point and the global market is projected to triple in the next five years, driven by high and rising levels of type-2 diabetes and obesity, aging populations, urbanization and public health initiatives: (2018-2030E) Global pharmaceutical companies dominate todays production: With ~300 clinical trials around the world, research continues into applications to other metabolic disorders, cardiovascular and kidney disease and neurological conditions
Dehydration can exacerbate musculoskeletal discomfort and potentially lead to kidney problems
Notably, no single GLP-1RA was superior to the others in preserving lean mass
Researchers have also found that oxidative stress may be the culprit behind some cases of major depressive disorder and other psychiatric disorders, including schizophrenia, bipolar, and psychosis
That is a pretty impressive response that you wont get from taking a GLP-1 injectable